Thrombotic events in severe FXII deficiency in comparison with unaffected family members during a long observation period

  • Antonio GirolamiEmail author
  • Silvia Ferrari
  • Elisabetta Cosi
  • Bruno Girolami
  • Maria Luigia Randi


To investigate the occurrence of thrombotic events (myocardial infarction, deep vein thrombosis or ischemic stroke) in a group of 39 cases of severe FXII deficiency during a mean 22.5 years follow-up. All patients seen in Padua during the years 1968–2006 will the object of this investigation. FXII was less than or 1% of normal in all cases. Factor FXII activity in unaffected family members was 98% (range 90–140%). No patient or control had a thrombotic event in the past and none were on anticoagulant therapy. FV Leiden was present in one patient and in two controls whereas the G to A20210 prothrombin polymorphism was absent in both groups. There was one death among the patients (breast cancer) and one among the control (car accident). There were two thrombotic events (myocardial infarction and deep vein thrombosis) in the patient group and three (myocardial infarction and two deep vein thrombosis) in the control group. Heterozygous FV Leiden was present in the patient who had venous thrombosis, One of the two control subjects who developed venous thrombosis had heterozygous FV Leiden and was on oral contraception. The second control subject who developed venous thrombosis was on oral contraception and had varicose veins. No ischemic stroke was observed in the patients or controls. Periods of immobilization were 42 days and 38 days, respectively for FXII deficient patients and for the controls. Patients with severe FXII deficiency may present thrombotic events but these are similar to these presented by unaffected family members. As a consequence it may be stated that severe FXII deficiency does not appear to effect thrombotic events.


Thrombosis FXII deficiency Contact phase Coagulation 



The study was supported in part (secretarial assistance) by the “Associazione Emofilia ed altre Coagulopatie delle tre Venezie”.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was performed according to the Helsinky Convention and its ethical standards.


  1. 1.
    Ratnoff OD, Colopy JE (1955) A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Investig 34:602–613CrossRefGoogle Scholar
  2. 2.
    Ratnoff MD, Busse RJ, Sheon RP (1968) The demise of John Hageman. N Engl J Med 279:760–761CrossRefGoogle Scholar
  3. 3.
    Girolami A, de Marco L, Dal Bo Zanon R, Patrassi G, Cappellato MG (1985) Rarer quantitative and qualitative abnormalities of coagulation. Clin Haematol 14:385–411Google Scholar
  4. 4.
    Goodnough LT, Saito H, Ratnoff OD (1983) Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases. Medicine (Baltimore) 62:248–255CrossRefGoogle Scholar
  5. 5.
    Lämmle B, Wuillemin WA, Huber I, Krauskopf M, Zürcher C, Pflugshaupt R, Furlan M (1991) Thromboembolism and bleeding tendency in congenital factor XII deficiency—a study on 74 subjects from 14 Swiss families. Thromb Haemost 65:117–121CrossRefGoogle Scholar
  6. 6.
    Dyerberg J, Stoffersen E (1980) Recurrent thrombosis in a patient with factor XII deficiency. Acta Haematol 63:278–282CrossRefGoogle Scholar
  7. 7.
    Vergnes C, Lorient-Roudaut MF, Haissaguerre M, Roudaut R, Wicker P, Boisseau MR, Dallocchio M (1985) Thrombophlebitis and pulmonary embolism in congenital factor XII deficiency. Arch Mal Coeur Vaiss 78:440–443Google Scholar
  8. 8.
    Speicher L, Philipp W, Kunz FJ (1992 Jul) Factor XII deficiency and central retinal vein occlusion. Lancet 340:237CrossRefGoogle Scholar
  9. 9.
    Lodi S, Isa L, Pollini E, Bravo AF, Scalvini A (1984) Defective intrinsic fibrinolytic activity in a patient with severe factor XII-deficiency and myocardial infarction. Scand J Haematol 33:80–82CrossRefGoogle Scholar
  10. 10.
    Barcat D, Beureau C, Bernard J (2001) Déficit familial en facteur XII isolé dècouvert devant une thrombose veineuse profonde du member supérieur. Rev Med Interne 22:200–202CrossRefGoogle Scholar
  11. 11.
    Zeerleder S, Schloesser M, Redondo M, Wuillemin WA, Engel W, Furlan M, Lämmle B (1999) Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency–a study on 73 subjects from 14 Swiss families. Thromb Haemost 82:1240–1246CrossRefGoogle Scholar
  12. 12.
    Koster T, Rosendaal FR, Briët E, Vandenbroucke JP (1994) John Hageman’s factor and deep-vein thrombosis: Leiden thrombophilia study. Br J Haematol 87:422–424CrossRefGoogle Scholar
  13. 13.
    Girolami A, Pellati D, Lombardi AM (2005) FXII deficiency is neither a cause of thrombosis nor a protection from thrombosis. Am J Ophthalmol 139:578–579CrossRefGoogle Scholar
  14. 14.
    Girolami A, Randi ML, Gavasso S, Lombardi AM, Spiezia F (2004) The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature. J Thromb Thrombolysis 17:139–143, 2004CrossRefGoogle Scholar
  15. 15.
    Girolami A, Morello M, Girolami B, Lombardi AM, Bertolo C (2005) Myocardial infarction and arterial thrombosis in severe (homozygous) FXII deficiency: no apparent causative relation. Clin Appl Thromb Hemost 11:49–53CrossRefGoogle Scholar
  16. 16.
    Girolami A, Candeo N, De Marinis GB, Bonamigo E, Girolami B (2011) Comparative incidence of thrombosis in reported cases of deficiencies of factors of the contact phase of blood coagulation. J Thromb Thrombolysis 31:57–63CrossRefGoogle Scholar
  17. 17.
    Girolami A, Cosi E, Santarossa C, Ferrari S, Lombardi AM (2016) Thrombotic events in asymptomatic FXII deficiency versus symptomatic FXI deficiency: surprising observations. Acta Haematol 136:118–122CrossRefGoogle Scholar
  18. 18.
    Girolami A, Gavasso S, Pacquola E, Cabrio L, Lombardi AM, Girolami B (2005) Comparable levels of activity and antigen in factor XII deficiency: a study of 21 homozygotes and 58 heterozygotes. Clin Appl Thromb Hemost 11:335–338CrossRefGoogle Scholar
  19. 19.
    Lombardi AM, Bortoletto E, Scarparo P, Scapin M, Santarossa L, Girolami A (2008) Genetic study in patients with factor XII deficiency: a report of three new mutations exon 13 (Q501STOP), exon 14 (P547L) and – 13C> T promoter region in three compound heterozygotes. Blood Coagul Fibrinolysis 19:639–643CrossRefGoogle Scholar
  20. 20.
    Girolami A, Scarpa R, Lazzarin M, Brunetti A (1968) Coagulopatia da deficienza di Fattore di Hageman (factor XII) prima ossrvazione in Italia.Riv. Crit Clin Med 58:265–278Google Scholar
  21. 21.
    Girolami A, Molaro G, Lazzarin M, Scarpa R, Brunetti A (1970) A “new” congenital haemorrhagic condition due to the presence of an abnormal factor X (factor X Friuli): study of a large kindred. Br J Haematol 19:179–192CrossRefGoogle Scholar
  22. 22.
    Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369(6475):64–67CrossRefGoogle Scholar
  23. 23.
    Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703Google Scholar
  24. 24.
    Girolami A, Scarparo P, Candeo N, Lombardi AM (2010) Congenital prekallikrein deficiency. Expert Rev Hematol 3:685–695CrossRefGoogle Scholar
  25. 25.
    Girolami A, Ferrari S, Cosi E, Girolami B (2018) Cardiovascular diseases in congenital prekallikrein deficiency: comparison with other chance-associated morbidities. Blood Coagul Fibrinolysis 29:423–428Google Scholar
  26. 26.
    Girolami A, Simioni P, Scarano L, Girolami B, Zerbinati P (2000) Symptomatic combined homozygous factor XII deficiency and heterozygous factor V Leiden. J Thromb Thrombolysis 9:271–275CrossRefGoogle Scholar
  27. 27.
    Maurin N, Schunkert H, Sieberth HG (1988) Thrombophilia with a combination of antithrombin III and factor XII deficiency. Thromb Haemost 60:127CrossRefGoogle Scholar
  28. 28.
    Miljic P, Colovic M, Boskovic D, Rakicevic Lj DV (2002) Combined severe factor XII deficiency and homozygous factor V Leiden mutation in a patient with venous thrombosis. Thromb Res 106:265–267CrossRefGoogle Scholar
  29. 29.
    Saito H, Scott J, Movat HZ, Scialla SJ (1979) Molecular heterogeneity of hageman trait (factor XII deficiency): evidence that two of 49 subjects are cross-reacting material positive (CRM+). J Lab Clin Med 94:256–265Google Scholar
  30. 30.
    Wuillemin WA, Furlan M, Stricker H, Lämmle B (1992) Functional characterization of a variant factor XII (F XII Locarno) in a cross reacting material positive F XII deficient plasma. Thromb Haemost 67:219–225CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of MedicineUniversity of Padua Medical SchoolPaduaItaly
  2. 2.Division of MedicinePadua City HospitalPaduaItaly

Personalised recommendations